Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
COVID-19
•
Psychiatry
•
Consultation-Liaison Psychiatry
•
General Outpatient Psychiatry
What pharmacologic and non-pharmacologic strategies have you found helpful in managing brain fog following COVID-19 infection?
Related Questions
When do you consider incorporating an antihistamine into the treatment of patients with long COVID–related neuropsychiatric symptoms?
Would you consider changing management for a patient with bipolar disorder stable on an antipsychotic who is on anticoagulation after a recent PE or VTE?
When do you recommend HLA testing prior to prescribing lamotrigine, carbamazepine, or oxcarbazepine to patients of Asian descent?
How do you manage patients who develop SIADH secondary to an SSRI but have had a strong positive response to that same medication?
What do you recommend as a first-line antidepressant in patients with major depressive disorder and migraines?
How do you manage patients with co-occurring ADHD and cardiac concerns?
How do you approach diagnosing suspected early tardive dyskinesia with minimal positive findings on AIMS examination?
How do you balance the risks and benefits of stimulant treatment in patients with poorly controlled hypertension?
How do you approach the management of behavioral disturbance/aggression in patients with a recent traumatic brain injury?
How do you approach firearm safety counseling for outpatients with elevated suicide risk who do not meet the criteria for involuntary psychiatric hospitalization?
